T-Cypher Bio is an early-stage biotechnology company. T-Cypher Bio we believe that TCR-based therapeutics have the potential to transform the treatment of solid tumors, as well as autoimmune, inflammatory, and infectious diseases. Yet challenges in the identification of therapeutically relevant targets and TCRs have limited the application of suchtherapies.T-Cypher’s integrated platform, D-Cypher, overcomes these challenges.

Biotechnology

T-Cypher Bio

Thomas L. Andresen

Sarah Leonard

Teams at T-Cypher Bio

Research and Development

Leadership Team